---
title: Clinical Information - Eyerising International
description: Clinical evidence for RLRL therapy. 15+ published trials reporting up to 87.7% reduction in axial elongation across multi-ethnic paediatric cohorts.
image: https://eyerisinginternational.com/hubfs/eri-web/images/og-default.png
---

I am not an eye-care professional I am an eye-care professional

 Viewing the International site.

[![Eyerising International](https://eyerisinginternational.com/hubfs/eri-web/logo-white.png)](https://eyerisinginternational.com/?hsLang=en)

[Home](https://eyerisinginternational.com/?hsLang=en)

[About Us](https://eyerisinginternational.com/about?hsLang=en)

[About Eyerising](https://eyerisinginternational.com/about?hsLang=en) [Our Story](https://eyerisinginternational.com/story?hsLang=en) [Purpose, Mission & Values](https://eyerisinginternational.com/purpose?hsLang=en) [Our Team](https://eyerisinginternational.com/team?hsLang=en) [What is Myopia?](https://eyerisinginternational.com/myopia?hsLang=en) [Meet Willow](https://eyerisinginternational.com/willow?hsLang=en)

[Our Device](https://eyerisinginternational.com/device?hsLang=en)

[Our Device](https://eyerisinginternational.com/device?hsLang=en) [Safety Information](https://eyerisinginternational.com/safety?hsLang=en) [Regulatory](https://eyerisinginternational.com/regulatory?hsLang=en)

[News](https://eyerisinginternational.com/news?hsLang=en)

[Latest News](https://eyerisinginternational.com/news?hsLang=en) [Clinical Information](https://eyerisinginternational.com/clinical-info?hsLang=en) 

[Events](https://eyerisinginternational.com/events?hsLang=en)

[Contact](https://eyerisinginternational.com/contact?hsLang=en)

[Contact Us](https://eyerisinginternational.com/contact?hsLang=en) [Find a Clinic](https://eyerisinginternational.com/clinics?hsLang=en) [FAQs](https://eyerisinginternational.com/faqs?hsLang=en)

[Get in Touch](https://eyerisinginternational.com/contact?hsLang=en)

[Home](https://eyerisinginternational.com/?hsLang=en) [About Us](https://eyerisinginternational.com/about?hsLang=en) [Our Story](https://eyerisinginternational.com/story?hsLang=en) [Purpose, Mission & Values](https://eyerisinginternational.com/purpose?hsLang=en) [Our Team](https://eyerisinginternational.com/team?hsLang=en) [What is Myopia?](https://eyerisinginternational.com/myopia?hsLang=en) [Meet Willow](https://eyerisinginternational.com/willow?hsLang=en) [Our Device](https://eyerisinginternational.com/device?hsLang=en) [Safety Information](https://eyerisinginternational.com/safety?hsLang=en) [Regulatory Approval](https://eyerisinginternational.com/regulatory?hsLang=en) [News](https://eyerisinginternational.com/news?hsLang=en) [Clinical Information](https://eyerisinginternational.com/clinical-info?hsLang=en) [Events](https://eyerisinginternational.com/events?hsLang=en) [Contact Us](https://eyerisinginternational.com/contact?hsLang=en) [Find a Clinic](https://eyerisinginternational.com/clinics?hsLang=en) [FAQs](https://eyerisinginternational.com/faqs?hsLang=en) [Get in Touch](https://eyerisinginternational.com/contact?hsLang=en)

# For Eye-Care Professionals

 This page is intended for eye-care professionals. Please confirm your role using the toggle at the top of the page to view this content. 

[Return to Homepage](https://eyerisinginternational.com/?hsLang=en)

For Eye-Care Professionals

# Clinical Information

 Evidence-based insights from 20+ clinical trials across multiple ethnicities.

## Clinical Evidence

 The Eyerising Myopia Management Device and RLRL therapy have been the subject of multiple published clinical and real-world studies conducted internationally. These studies have explored the safety and efficacy of RLRL therapy as an intervention for managing childhood myopia, involving diverse paediatric populations and research settings across different ethnicities.

87.7%

Reduction in Axial Elongation

 Up to 87.7% reduction in axial elongation reported in clinical studies, representing one of the highest efficacy outcomes documented among approved myopia management interventions.1

Multi-Ethnic

Cohort Diversity

 Clinical trials have been conducted across multi-ethnic cohorts spanning Asia, Europe, and Australia, providing evidence for treatment efficacy across diverse patient populations.

Standalone + Adjunctive

Trial Designs

 Evidence encompasses both standalone RLRL therapy trials and adjunctive therapy trials in combination with orthokeratology, soft contact lenses, and spectacle lenses.

Up to 5 Years

Long-Term Follow-Up

 Long-term follow-up data of up to 5 years is available, providing a safety and efficacy evidence base unique among myopia management modalities.

1 Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, Zhang J, Xiong R, Yuan Y, Zeng J, Morgan IG, He M. Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial. Ophthalmology. 2022;129(5):509-19.

## Research Programs

 The Eyerising clinical evidence base spans a range of study designs, reflecting the rigor expected of an approved medical device.

### Randomised Controlled Trials

 Pivotal RCTs with sham-controlled or active-comparator designs, providing the highest level of clinical evidence for the efficacy and safety of RLRL therapy in paediatric myopia management.

### Real-World Evidence Studies

 Prospective real-world evidence studies capturing treatment outcomes across diverse clinical settings, patient demographics, and co-prescribed interventions. Data includes tens of thousands of patients across 40+ countries.

### Combination Therapy Trials

 Trials investigating RLRL in combination with other established myopia management modalities:

- RLRL + Orthokeratology
- RLRL + Soft Multifocal Contact Lenses
- RLRL + Myopia Control Spectacle Lenses

### Long-Term Safety and Efficacy Monitoring

 Extended follow-up programs tracking ocular structural integrity, visual function, and sustained efficacy at up to 5-year time points. Post-market surveillance programs complement controlled trial data with continuous safety monitoring.

## Research Collaborations

 Ongoing investigations are being conducted in collaboration with academic and clinical partners across Asia, Europe, and Australia, including trials assessing RLRL as both a standalone and adjunctive therapy. Peer-reviewed publications to date have reported favourable trends in slowing myopia progression and maintaining visual outcomes within established safety parameters.

 All research is carried out under appropriate ethics approvals and in accordance with recognised international standards for medical device evaluation.

## Access Clinical Resources

 For key publications, paper summarises and updates on emerging data, please contact us on [info@eyerisinginternational.com](mailto:info@eyerisinginternational.com).

[Request Clinical Resources](https://eyerisinginternational.com/contact?hsLang=en)

![Eyerising International](https://eyerisinginternational.com/hubfs/eri-web/logo-white.png)

 Advancing myopia management through repeated low-level red-light therapy.

#### Company

- [About Us](https://eyerisinginternational.com/about?hsLang=en)
- [Our Team](https://eyerisinginternational.com/team?hsLang=en)
- [Our Story](https://eyerisinginternational.com/story?hsLang=en)
- [News](https://eyerisinginternational.com/news?hsLang=en)
- [Events](https://eyerisinginternational.com/events?hsLang=en)

#### Resources

- [Our Device](https://eyerisinginternational.com/device?hsLang=en)
- [Safety Information](https://eyerisinginternational.com/safety?hsLang=en)
- [Regulatory Approval](https://eyerisinginternational.com/regulatory?hsLang=en)
- [FAQs](https://eyerisinginternational.com/faqs?hsLang=en)
- [Find a Clinic](https://eyerisinginternational.com/clinics?hsLang=en)

#### Contact

 Suite 2.05, 9/11 Claremont St  
 South Yarra VIC 3141, Australia 

[info@eyerisinginternational.com](mailto:info@eyerisinginternational.com)

[LinkedIn](https://au.linkedin.com/company/eyerising-international)

THIS PRODUCT IS NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE

Ask your optometrist or ophthalmologist for advice to see if this product is right for your child.

Outcomes may vary for each patient. The Eyerising Myopia Management Device is exclusively available through eye care professionals (e.g. optometrists, ophthalmologists) for home use.

© 2026 Eyerising International. All rights reserved.

[LinkedIn](https://au.linkedin.com/company/eyerising-international) [Privacy Policy](https://eyerisinginternational.com/legal?hsLang=en) [Terms & Conditions](https://eyerisinginternational.com/legal?hsLang=en)

## Welcome to Eyerising International

To show you the most relevant information, please confirm which best describes you.

I am not an Eye-Care Professional

I am an Eye-Care Professional

## Disclaimer

This website is intended for use by eye care professionals only. By agreeing and proceeding, you are declaring you are a registered eye care professional. If you are not a registered eye care professional, do not proceed.

I Agree

I Disagree

```json
{
  "@context" : "https://schema.org",
  "@type" : "MedicalOrganization",
  "address" : {
    "@type" : "PostalAddress",
    "addressCountry" : "AU",
    "addressLocality" : "South Yarra",
    "addressRegion" : "VIC",
    "postalCode" : "3141",
    "streetAddress" : "Suite 2.05, 9/11 Claremont St"
  },
  "contactPoint" : {
    "@type" : "ContactPoint",
    "contactType" : "customer service",
    "email" : "info@eyerisinginternational.com"
  },
  "description" : "Australian MedTech company advancing repeated low-level red-light (RLRL) therapy for childhood myopia management.",
  "foundingDate" : "2020",
  "logo" : "https://43619611.fs1.hubspotusercontent-ap1.net/hubfs/43619611/eri-web/logo-white.png",
  "name" : "Eyerising International",
  "sameAs" : [ "https://www.linkedin.com/company/eyerising-international" ],
  "url" : "https://eyerisinginternational.com"
}
```